Wells Fargo analyst Mohit Bansal lowered the firm’s price target on Bristol Myers (BMY) to $60 from $65 and keeps an Equal ...
Medicare beneficiaries using lower-priced negotiated drugs experienced out-of-pocket savings under the Medicare Drug Price ...
Bristol Myers Squibb is making a $4.1 billion bet on radiopharmaceutical cancer drugs ahead of a major patent cliff in 2028.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results